Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
CRWD 36.08CRM 43.7NVDA 19.71KEL.TO 0.09WPM.TO 2.71X.TO 0.015ODD 0.15CDI.PA-O 0
AbbVie Inc. (ABBV)

NYSE:ABBV

AbbVie Inc. (ABBV)

257.66
-5.24 (1.99%)
as of Aug 27, 2026, 5:02:07 pm Market Open.
336 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 27, 2026, 12:00 am

This summary was created by AI, based on 7 opinions in the last 12 months.

AbbVie Inc. is receiving positive reviews from experts, highlighting the company's robust performance despite the patent expiration of its blockbuster drug, Humira. The recent Q2 earnings report showcased an impressive total net revenue increase of 10.2%, driven by significant sales growth from new drugs like Skyrizi and Rinvoq. Experts note that AbbVie has successfully managed the transition by replacing lost revenues with innovative products, projecting strong revenue growth of 24% going forward. The stock has seen fluctuations, appreciating 6% in the past month and 15% over the past year, establishing itself as a solid holding in the healthcare sector with less execution risk. Overall, the sentiment is optimistic about AbbVie's future prospects, fueled by a promising pipeline and effective management strategies addressing current challenges.

consensus icon
Consensus
Positive
valuation icon
Valuation
Fair Value
review icon
Similar
PFE
SELL

AbbVie Inc.(ABBV)

Jan 11, 2023
He used to own, but moved on because Humira coming off patent this year. Lower growth trajectory. Looks great on paper, but you have to get into the weeds to see where it might go, not where it's been.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$156.88

Stock price when the opinion was issued

$258.49

As of Aug 27, 2026. Market Open.

0
DON'T BUY

AbbVie Inc.(ABBV)

Dec 13, 2022
A good pharma, much larger after buying Allergan. They were spun off years ago from another company because major drug, Humira, was a cash cow. Because Humira has become 60-65% of all revenues, AbbVie smartly bought Allergan (Botox). Now, Humira amounts to 45% of revenues, and Humira went off-patent last year. A few big drugs are trying to fill that hole. He owned this before, but feels it's too risky now.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$165.41

Stock price when the opinion was issued

$258.49

As of Aug 27, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

Nov 04, 2022
Better investment than Pfizer. Demand in China will grow. Cancer side of business will continue to grow. Aesthetics business will also grow.
Photo of Shane ObataShane ObataUnlock Rating
$145.29

Stock price when the opinion was issued

$258.49

As of Aug 27, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

Oct 28, 2022
They report today. She trimmed it earlier this year to take profits. She really likes healthcare--traditionally defensive but also a disruptive/growth space. MRNA has spotlighted how much more can be done in therapeutics. It's a growth and value trade.
Photo of Shannon Saccocia, CIO, Boston PrivateShannon Saccocia, CIO, Boston Private
Owned
Unlock Rating
$146.68

Stock price when the opinion was issued

$258.49

As of Aug 27, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

Oct 28, 2022
BMY and AbbVie The line is blurred between biotech and pharma. He likes both spaces and both stocks. Aging demographics means more and more drugs. Both are have solid valuations. They pay income but also offer capital appreciation.
Photo of Jim LebenthalJim Lebenthal
Owned
Unlock Rating
$146.68

Stock price when the opinion was issued

$258.49

As of Aug 27, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

Oct 21, 2022
Really likes it. Pays a nearly 4% dividend yield and 8% free cash flow. Has a strong portfolio of drugs. Skyrizi is growing like a weed. Likes it going into earnings.
Photo of Jason Snipe, CIO, Odyssey Capital AdvisorsJason Snipe, CIO, Odyssey Capital Advisors
Owned
Unlock Rating
$147.06

Stock price when the opinion was issued

$258.49

As of Aug 27, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

Oct 12, 2022
He owns it for the dividend, pricing power and it has recreated after several missteps. Definitely holding this.
Photo of Joe TerranovaJoe Terranova
Owned
Unlock Rating
$140.32

Stock price when the opinion was issued

$258.49

As of Aug 27, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

Oct 07, 2022
Headwind ahead as major product offering facing a patent challenge. Sales are remaining strong with the company regardless. Cosmetics business (Botox) very resilient, even during a recession. Pipeline of new drug development is also looking good. Good time to buy shares. Strong dividend as well.
Photo of JoAnne FeeneyJoAnne FeeneyUnlock Rating
$138.76

Stock price when the opinion was issued

$258.49

As of Aug 27, 2026. Market Open.

0
SELL

AbbVie Inc.(ABBV)

Sep 09, 2022
Good time to sell the stock. Has sold shares. Doesn't see positive upside for the stock. Numbers of the surface (dividend yield, cash flow yield) look good. Problem is that one of major drugs loses patent next year. Building pipeline of R&D in consumer drugs.
Photo of Gordon ReidGordon ReidUnlock Rating
$141.42

Stock price when the opinion was issued

$258.49

As of Aug 27, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

Aug 29, 2022
A great CEO. Pays a 4% yield. He isn't worried about Humira coming off patent, because they have a lot of cash.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$135.71

Stock price when the opinion was issued

$258.49

As of Aug 27, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

Aug 19, 2022
He likes healthcare and likes their 4.1% dividend. It's cheap at 10x earnings. There are concerns about their big drug coming off patent, but management can transition their main drug coming off patent.
Photo of Rob Sechan, Managing Partner, New Edge CapitalRob Sechan, Managing Partner, New Edge Capital
Owned
Unlock Rating
$142.01

Stock price when the opinion was issued

$258.49

As of Aug 27, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

Jul 29, 2022
Reported a mix quarter today. Though shares are down today, it's still up 5% YTD. AbbVie re-affirmed guidance. She wouldn't read too much into the quarter.
Photo of Bryn TalkingtonBryn Talkington
Owned
Unlock Rating
$143.51

Stock price when the opinion was issued

$258.49

As of Aug 27, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

Jul 29, 2022
Healthcare is his favourite defensive sector. AbbVie needs to provide clear guidance about the erosion curve in Humira, its top drug (that will go off-patent next year). A popular drug going generic isn't necessarily a death sentence for the stock. He thinks management can pull this off. Sales declined only slightly, despite a 40% drop in Humira. Today, they announced a $2.2 billion settlement in opiod litigation (the opiod epidemic) which removes that overhang. It's probably a pretty good buy here.
Photo of Rob Sechan, Managing Partner, New Edge CapitalRob Sechan, Managing Partner, New Edge Capital
Owned
Unlock Rating
$143.51

Stock price when the opinion was issued

$258.49

As of Aug 27, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

Jul 29, 2022
A great name in pharma that reported today. Their neuroscience division is up 14% quarter over quarter, while cash flow yield is above 7%. It's performed relatively well vs. the market YTD. He still likes the name.
Photo of Jason Snipe, CIO, Odyssey Capital AdvisorsJason Snipe, CIO, Odyssey Capital Advisors
Owned
Unlock Rating
$143.51

Stock price when the opinion was issued

$258.49

As of Aug 27, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

Jul 28, 2022
His long-term concern comes out of Washington which is proposing drug-pricing laws. One mixed quarter doesn't worry him; the stock has been a war horse. AbbVie proves it can refill its pipeline.
Photo of Jim LebenthalJim Lebenthal
Owned
Unlock Rating
$149.75

Stock price when the opinion was issued

$258.49

As of Aug 27, 2026. Market Open.

0
Showing 46 to 60 of 178 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

PFE -0.14$28.16
NOW 11.49$137.29
BRK.B -0.81$504.1
FTS.TO -0.77$76.02
ATH.TO 0.155$10.835
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

CRWD 36.08$225.26
CRM 43.7$249.32
NVDA 19.71$229.37
KEL.TO 0.09$10.74
WPM.TO 2.71$219.05

Popular Articles

Latest Sell Signals

CLS.TO 18.7$444.86
TJX -1.62$135.21
ORCL -0.43$148.44
GAW-LSE 0$
BB.TO 0.77$11.57

Most Recent Experts

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Javed Mirza

Javed Mirza

Raymond James

Bill Baruch, Founder, Blue Line Capital

Bill Baruch, Founder, Blue Line Capital

Blue Line Capital

Karen Firestone, CEO, Aureus Asset Management

Karen Firestone, CEO, Aureus Asset Management

Aureus Asset Management

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like